TB on YouTube

Tuesday, March 11, 2014

Introduction


My name is Molly Cullen and I am a nursing student at Alverno College in Milwaukee, Wisconsin. In order to take a more specified approach into how the pathogenicity of certain microbes affects human life, I decided to write this blog on the infectious disease, Tuberculosis (TB). According to the World Health Organization (WHO), TB is the second leading cause of death from a single infectious agent, only after HIV (WHO Global Tuberculosis Report, 2013).

I chose TB as my topic because I never truly understood the hype about the disease. To me, TB was something like cholera or smallpox - something that has no relevance to modern life (unless you're playing Oregon Trail on your desktop computer...). However, through performing my research, I learned quite the opposite - TB greatly affects millions of lives today. In fact, "in 2012, an estimated 8.6 million people developed TB and 1.3 million died from the disease" (WHO, 2013).

A disease that causes this extent of morbidity and mortality around the world cannot be ignored. Therefore, I hope you find my blog not only to be informative, but also interesting! Enjoy.


Background Information on TB


Tuberculosis is an infectious, communicable disease that is caused by the bacterium Mycobacterium tuberculosis. This bacterium is an acid-fast rod, whose cell wall contains a waxy substance, called mycolic acid. In addition, M. tuberculosis is an obligate aerobe, which means it cannot survive without oxygen and needs oxygen for metabolism and growth. TB is most often contracted through inhaling the bacterium and can often go undetected by the affected individual. It is not until the particular individual's immune system is weakened, as with HIV or cancer, that the bacterium is activated and begins to harm the host (Tortora, Funke & Case, 2013, p.688). According to the Centers for Disease Control and Prevention (CDC), one-third of the world's population is currently infected with TB (2014).



Pathogenesis of TB 


The image below shows the effects of TB cells when the body's immune system fails to protect the body from the disease, so that the disease is able to progress lethally.






2004, Pearson Education, Inc. Retrieved from http://classes.midlandstech.com/carterp/courses/bio225/chap24/lecture4.htm



To summarize the image:


When the body cannot defend against the infection, the host isolates the pathogens in a separate lesion, called a tubercle, which heals very slowly. Due to the delay in healing time, the lesions become calcified. If the body's immune system continues to fail, the tubercle breaks down and the bacteria are released into the body, where they can affect many of the body's other systems. 


Statistics on the Prevalence of TB 


According to the WHO Global Tuberculosis Report 2013: 

  • 8.6 million people fell ill with TB in 2012, including 1.1 million cases of TB are among people living with HIV. 
  • 410,000 women died from TB in 2012, including 160,000 among women who were HIV-positive. TB is on of the top killers of women of reproductive age. 
  • An estimated 530,000 children became ill with TB and 74,000 children who were HIV-negative died of TB in 2012.
  • The TB mortality rate has decreased 45% since 1990, and the 2015 global target of a 50% reduction in mortality is now within reach. 
  • Access to TB care has expanded substantially since the mid-1990s. Between 1995 and 2012, 56 million people were successfully treated for TB in countries that had adopted the WHO TB strategy, saving 22 million lives. 

UN News Centre. (23 October 2013). Tuberculosis gains at risk due to millions of missed patients, drug resistance. Retrieved from https://www.un.org/apps/news//story.asp?NewsID=46313&Cr=tuberculosis&Cr1=#.Ux_ZICiGIzI




Treatment and Drug Resistance of TB 

(Tortora, Funke & Case, 2013, p.691)



In 1944, streptomycin was introduced as the first antibiotic used for tuberculosis treatment. However, since M. tuberculosis is extremely virulent, multi-drug therapy is necessary to avoid the generation of antibiotic-resistant strains. The first-line of defense consists of antibiotics like: 
  • Isoniazid*
  • Ethambutol
  • Pyrazinamide
  • Rifampin* 
(* are the most effective) 
While the second-line of defense can include several different antibiotics, including:
  • Aminoglycosides
  • Fluoroquinolones
  • Para-aminosalicylic acid (PAS)



When the strain of TB is susceptible to a first-line drug, it could be cured. However, many people do not take their antibiotics as prescribed, especially over a long period of time, as is required with the treatment of TB. The disadvantages with the second-line drugs is that they are less effective, can have many negative side effects, and are often unavailable in poorer countries with increased cases of TB. 

In the 1920s, a TB vaccine was released and was available to the public. However, in the United States, the vaccine is reserved only for young children that have had a negative skin test. The efficiency of the vaccine is highly variable - typically only effective in young children and not at all in adolescents or adults. 

Multi-Drug Resistant Tuberculosis (MDR-TB) 


The WHO defines MDR-TB as "a form of TB caused by bacteria that do not respond to, at least, isoniazid and rifampicin, the two most powerful, first-line (or standard) anti-TB drugs" (Tuberculosis, 2014). While second-line drugs can be effective in treating this form of TB, it is a very costly form of treatment and is not an affordable or realistic option for many people. The WHO reports that approximately 450,000 people developed MDR-TB in 2012. In addition, some strains that are resistant to second-line drugs have been discovered, called extensively drug resistant (XDR). These strains are "virtually untreatable and are emerging globally" (Tortora, Funke & Case, 2013, p. 691). 




The Five Priorities of the WHO in Addressing the TB Epidemic

  1. Reach the missed cases: about 3 million people with TB went unreported in 2012. It is key to identify these people so they can receive treatment. 
  2. Address MDR-TB as a public health crisis:increase availability of drugs and technology in countries with increased cases of MDR-TB
  3. Accelerate the response to TB/HIV
  4. Increase financing to close all resource gaps: $8 billion each year is necessary for a full response in low and middle-income countries.
  5. Ensure rapid uptake of innovations

References 


Centers for Disease Control and Prevention. (2014, March 7). Tuberculosis data and statistics. Retrieved from http://www.cdc.gov/tb/statistics/default.htm?s_cid=fb1804



Tortora, G.J., Funke, B.R., & Case, C.L. (2013). Microbiology: An introduction (11th ed.). Boston: Pearson.





World Health Organization. (2013). Global tuberculosis report. Retrieved from http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf?ua=1



World Health Organization. (2014). Tuberculosis. Retrieved from http://www.who.int/mediacentre/factsheets/fs104/en/